Radiation absorbed dose evaluation of [177Lu]Lu-DOTMP radiopharmaceutical in man based on biodistribution data in Wistar rats

Document Type : Original Paper


1 Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran

2 Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, Tehran, Iran



Introduction: Bone metastasis is the advanced stage of solid malignant tumors. Bone-avid beta-emitting radiopharmaceuticals such as lutetium-177-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid ([177Lu]Lu-DOTMP) are effectively utilized for bone pain palliation.

Materials and Methods: In this research, the radiation absorbed dose of [177Lu]Lu-DOTMP radiopharmaceutical was evaluated for adult men based on biodistribution data in Wistar rats. The Medical Internal Radiation Dosimetry (MIRD) dose calculation method and the Sparks and Aydogan methodology were applied.

Results: About 40% of the injected activity is accumulated on the surface of the trabecular and compact bones. Radiation absorbed doses of red bone marrow and osteogenic cells were estimated at 0.89±0.07 and 5.12±0.40 mGy/MBq, respectively. The maximum administrated activity was obtained at 32.2 MBq/kg (0.87 mCi/kg) of body weight with about 11.6 Gy absorbed dose of bone surface for a 70 kg adult man. The effective dose of [177Lu]Lu-DOTMP radiopharmaceutical was estimated at 0.19±0.02 mSv/MBq and the urinary bladder wall and kidneys absorbed doses were evaluated at about 0.20±0.02 mGy/MBq and 0.05±0.01 mGy/MBq, respectively.

Conclusion: This study indicated that [177Lu]Lu-‌DOTMP radiopharmaceutical can provide palliative care for bone metastases with low undesired doses to other normal tissues.


Main Subjects

Articles in Press, Accepted Manuscript
Available Online from 29 April 2024
  • Receive Date: 31 December 2023
  • Revise Date: 28 April 2024
  • Accept Date: 29 April 2024